Home > Selected Past Studies

SELECTED PAST STUDIES - ALL DISEASES

Study

Disease

type & number of samples

Specific Requirements

associated data required

HEM-1

Acute Myeloid Leukemia

Bone Marrow Mononuclear Cells

Retrospective

More than 20 subjects

  • Relapsed or refractory AML patients
  • 5-10 million BMMCs per subject
  • Viably frozen
  • Age, Gender, Ethnicity
  • Medical history
  • Diagnosis report

HEM-2

Acute Myeloid Leukemia

Whole Blood & PBMC

Prospective

More than 10 subjects

  • Relapsed or refractory AML patients
  • Samples collected before any treatment
  • 20 ml whole blood collected on 3 different types of collecting tubes.
  • PBMCs isolated right after blood collection and frozen at -80°C
  • Blood Samples per patient must be shipped immediately after collection
  • Age, Gender, Ethnicity
  • Treatment history
  • Diagnosis

HEM-3

Chronic Myeloid Leukemia

RNA

Retropective

More than 180 subjects treated by TKI

2 groups:

  • 50% cases with an event (death, loss of Response, appearance of mutation…)
  • 50% cases without an event (event-free at least 6 months after blood draw
  • Subjects treated by Tyrosine Kinase Inhibitors treatment
  • Demographic, diagnostic and medical data
  • Confirmed diagnosis of BCR-ABL positive Chronic Myeloid Leukemia
  • Treatment History and medical out-come

HEM-4

Diffuse Large B-Cell Lymphoma (DLBCL)

FFPE Blocks

Retrospective

More than 15 subjects

  • Lymph node biopsy tissue blocks
  • Subjects with newly diagnosed DLBCL
  • Demographic, diagnostic and medical data
  • Treatment History

HEM-5

Diffuse Large B Cell Lymphoma (DLBCL)

FFPE Blocks

Retrospective

More than 50 subjects

  • Lymph node biopsy tissue blocks
  • Relapsed and refractory DLBCL
  • Last line of therapy must have been chemotherapy based regimen
  • Age, Gender, Ethnicity
  • Date of collection
  • Clinical history
  • Age, Gender, Ethnicity
  • Date of collection
  • Clinical history
  • Pathology report
  • Information about response to last line of therapy (response and progression free survival)

HEM-6

Peripheral T-Cell Lymphoma

FFPE Blocks

Retrospective

At least 20 subjects

  • Lymph node biopsy tissue blocks from T-cell lymphomas:
  • Cutaneous
  • Angioimmunoblastic
  • Extranodal natural killer/ T-cell lymphoma
  • Nasal type
  • Enteropathy type
  • Subcutaneous panniculitis-like
  • Anaplastic large cell lymphoma
  • Age, Gender, Ethnicity
  • Clinical history
  • Pathology report

HEM-7

Mantle Cell Lymphoma

Peripheral Blood Mononuclear Cells and Isolated B-cells/Blasts

Retrospective

More than 10 subjects

  • Newly diagnosed untreated patients
  • Age, Gender, Ethnicity
  • Sample collection date (year only)
  • Clinical history
  • Diagnosis report

HEM-8

T-Cell Lymphoma

FFPE Blocks

Retrospective

More than 60 subjects

6 groups:

  • Adult T-Cell Leukemia/Lymphoma HTLV1+
  • NK/T Lymphoma, nasal type
  • Enteropathy-associated T Lymphoma
  • Peripheral T-Cell Lymphoma
  • T-Cell Lymphoma, NOS
  • Angioimmunoblastic T-Cell Lymphoma
  • Lymph nodes or biopsy tissue blocks
  • Age, Gender, Ethnicity
  • Medical history
  • Diagnosis report

HEM-9

Lymphoma (Pediatric)

FFPE Blocks

Prospective

More than 25 subjects

  • Lymph node biopsy or surgical resection tissue blocks
  • Age, Gender, Ethnicity
  • Sample collection date
  • Confirmed Pathological diagnosis
  • Date of initial diagnosis

HEM-10

ALK-positive Anaplastic Lymphoma

FFPE Blocks

Retrospective

More than 5 subjects

  • ALK mutated
  • Age, Gender, Ethnicity
  • Pathological diagnosis
  • Sample collection date
  • Used method for detection of ALK rearrangements

HEM-11

Multiple Myeloma

Frozen Bone Marrow Biopsy

Prospective

More than 20 subjects

2 groups:

  • Subjects with Relapsed or Refractory MM
  • Newly diagnosed MM subjects, treatment naïve
  • Patients under treatment at the time of collection
  • Age, Gender, Ethnicity
  • Sample collection date
  • Confirmation of Diagnosis
  • Treatment history

HEM-12

Multiple Myeloma

Frozen EDTA plasma-Red Blood Cell-lysed Bone Marrow Aspirate Cell Pellet-Bone Marrow FFPE Clot

Retrospective

More than 5 subjects 

  • Minimum of 0.5 mL of BMA to be used for cell pellet and FFPE clot samples
  • Age, Gender, Ethnicity
  • Clinical history
  • Pathology report

GI-1

Colorectal Cancer

FFPE Blocks with Known KRAS Mutation Status and Matched Plasma

Prospective

More than 200 subjects

  • Newly Diagnosed patients with Colorectal Cancer stage IV
  • Blood samples collected before treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • KRAS mutation status

GI-2

Colorectal Cancer

FFPE Blocks with Known MMR Status

Retrospective

More than 70 subjects

  • Known DNA mismatch repair (MMR) status
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-3

Colorectal Cancer

FFPE Blocks

Retrospective

More than 20 subjects

2 tissue samples per patient:

  • One pre- treatment
  • One post-treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

GI-4

Colorectal Cancer

FFPE Blocks

Retrospective

More than 500 subjects

  • Primary tumor
  • Stage IIA or higher
  • Surgery for primary colon cancer with a minimum of three years follow up, not treated with adjuvant chemotherapy
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

GI-5

Colorectal Cancer

FFPE slides

Retrospective

More than 60 subjects

  • FFPE sections (10 slides of 10 μm) and one H&E stained slide
  • Patients who underwent chemotherapy (surgery excluded): 50% responders & 50% non responders
  • Samples collected before treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Radiological data with tumor and metastases sizes before and after/during the treatment

GI-6

Colorectal Cancer

Freshly Resected Tumor Tissue

Prospective

5 subjects

  • Adenocarcinoma
  • Any stage
  • Sample size: 2 g
  • Samples must be received fresh within 48 hour of resection
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-7

Colorectal Cancer and Polyps

Serum

Retrospective

More than 60 subjects:

3 groups:

  • Patients with Colorectal Cancer stage I & II
  • Patients with Adenomatous Polyps
  • Patients with Hyperplastic Polyps
  • Group CRC: Samples collected before any treatment o surgery
  • Group 2 & 3: Samples collected at time of colonoscopy
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-8

Colorectal Cancer

Serum

Prospective

More than 70 subjects

Patients treated with EGFR inhibitors:

  • 50% patients with no adverse events
  • 50% patients with diverse events
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Date of treatment initiation
  • Date and Description of adverse events

GI-9

Rectal Cancer

Serum

Retrospective

More than 100 subjects

  • Locally Advanced Rectal Carcinoma (LARC), Stages II/III
  • Samples collected before treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and a 3 years medical out-come

GI-10

Gastric Cancer

FFPE Blocks and Matched PBMC

Retrospective

More than 50 subjects

  • 2 groups: with or without relapse within 5 years
  • Samples collected at diagnosis, before start of any treatment
  • FFPE blocks must allow to cut at least 50 sections
  • PBMC isolated from 10 mL of blood
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Biomarker status: EGFR, KRAS

GI-11

Gastric Cancer

Frozen Tissue

Retrospective

More than 50 subjects

  • 2 samples per subject (greater than 0.5 gJ Gastric tumor and Normal Adjacent Tumor tissues
  • Age, Gender, Ethnicity
  • Sample collection date
  • Weight, height, BMI

GI-12

Gastric Cancer

Whole Blood

Retrospective

More than 10 subjects

  • Stage III or IV
  • Samples collected from patients not under treatment: collected at time of diagnostic before any treatment
  • Whole blood collected on specific preservative tubes
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-13

Adenocarcinoma of the Esophagogastric Junction

FFPE Blocks

Retrospective

More than 40 subjects

  • Adenocarcinoma of the Esophagogastric Junction
  • Stage IIIB or higher
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-14

Esophagus Carcinoma

FFPE Blocks

Retrospective

More than 160 subjects

2 groups:

  • Adenocarcinomas
  • Squamous Cell Carcinomas
  • Stage III or higher
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

GI-15

Hepatocellular Carcinoma

Tissue Micro-Arrays

Retrospective

More than 180 subjects

  • Patients newly diagnosed and treatment naïve
  • All stages must be provided
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

GI-16

Liver Cancer

FFPE Blocks AND Matched Serum

Retrospective

More than 50 subjects

  • Hepatocellular Carcinoma, Cholangiocarcinoma, metastatic adenocarcinoma or carcinoma…
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-17

Hepatocellular Carcinoma

FFPE Blocks

Retrospective

More than 200 subjects

  • Asian patients only
  • Child Pugh Score < or equal to 7 (one-year survival rate >80%)
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • Child Pugh score

GI-18

Hepatocellular Carcinoma

FFPE Blocks with Matched PBMC

Retrospective

More than 40 subjects

  • 2 groups: with or without relapse within 5 years
  • Samples collected at diagnosis, before start of any treatment
  • FFPE blocks must allow to cut at least 50 sections PBMC isolated from 10 mL of blood
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

GI-19

Hepatocellular Carcinoma

FFPE Slides

Retrospective

More than 20 subjects

  • Asian patients only
  • Primary HCC
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-20

Hepatocellular Carcinoma

FFPE Blocks and Matched Serum

Retrospective

More than 10 subjects

  • Patients with primary Hepatocellular Carcinoma (HCC)
  • Advanced stage/higher grade
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-21

Pancreatic Adenocarcinoma

Frozen Tissue and Matched Plasma

Retrospective

More than 20 subjects

  • Any stage
  • Frozen tissue of primary tumor
  • Specimen collected at time of diagnosis
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • KRAS mutation status

GI-22

Pancreatic Adenocarcinoma

FFPE Blocks and Matched Serum

Retrospective

More than 50 subjects

  • Pancreatic ductal adenocarcinoma
  • Any stage
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-23

Neuroendocrine Pancreatic Cancer

FFPE Blocks

Retrospective

More than 20 subjects

  • Pancreatic neuroendocrine tumor
  • Advanced stages
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-24

Metastatic Pancreatic Cancer

FFPE Blocks

Retrospective

More than 30 subjects

  • Metastatic pancreatic ductal adenocarcinoma
  • Core needle biopsies of pancreatic ductal adenocarcinoma metastasis from liver
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

GI-25

Pancreatic Cancer

Serum

Retrospective

More than 300 subjects

11 Groups:

  • Resected pancreatic adenocarcinoma
  • Locally advanced pancreatic cancer
  • Metastatic pancreatic cancer
  • Recurrent pancreatic cancer
  • Endocrine pancreatic cancer
  • Symptomatic patients with a negative diagnosis of pancreatic cancer
  • Asymptomatic patients who had incidental findings of a pancreatic cancer identified by abdominal imaging discovered during a work-up for a different medical problem
  • Heriditary pancreatic cancer
  • Pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms, or mucinous cystic neoplasms
  • Choledocholithiasis, cholelithiasis
  • Chronic pancreatitis
  • Frozen serum at -80C
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

BOU-1

Breast Cancer Stage IV

FFPE Blocks

Retrospective

More than 360 subjects

  • 50% Progesterone Receptor-Positive
  • 50% Progesterone Receptor-Negative
  • Stage IV Breast Cancer
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Cold ischemia time
  • ER and Her2 status

BOU-2

Breast Cancer

FFPE Blocks and PBMC

Retrospective

More than 40 subjects

  • Breast Adenocarcinoma
  • Peripheral Blood Mononuclear cells (PBMC), if available
  • Primary tumor tissue only
  • PBMC isolated from 10 mL of blood collected at diagnosis
  • Age, ethnicity
  • Sample collection date
  • Date of diagnosis
  • Confirmed clinical diagnosis
  • Type of treatment
  • Medical Outcome (presence/absence of relapse or death) within 5 years

BOU-3

Breast Cancer

FFPE Blocks

Retrospective

More than 10 subjects

  • Triple-Negative Breast Cancer

Primary tumor tissue only 2 FFPE blocks:

  • One pre-chemotherapy
  • One post-chemotherapy
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Treatment history and overall survival data

BOU-4

Breast Cancer

FFPE Blocks

Retrospective

More than 20 subjects

  • Invasive Breast Cancer Any stage, Grade 1 or 2
  • Tissue biopsies
  • Demographic, diagnostic data
  • TNM
  • Sample collection date

BOU-5

Breast Cancer

Fresh Frozen Tissue

Prospective

More than 12 subjects

  • Triple-Negative Breast Cancer (TNBC)
  • Any stage
  • Age, ethnicity
  • Height, weight
  • Current treatment
  • Concurrent diseases
  • Pathology Report

BOU-6

Breast Cancer

Fresh Frozen Lymph Nodes

Retrospective

More than 270 subjects

3 groups:

  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Lymph node weight > 50 mg
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Lymph Node weight

BOU-7

Breast Cancer

Whole Blood

Prospective

More than 30 subjects

3 groups:

  • Breast Cancer
  • Gastric Cancer
  • Control (Healthy) Subjects
  • Subjects with stage III or IV cancer
  • Blood collected at time of diagnosis prior to any treatment or between treatment cycles
  • Whole blood samples must be collected on specific Tubes
  • Age, gender, ethnicity
  • Sample collection date
  • Date of diagnosis
  • Confirmed clinical diagnosis

BOU-8

Ovarian Cancer Cervical Cancer

FFPE Blocks

Retrospective

More than 6 subjects

2 groups:

  • 50% Ovarian Transitional Carcinoma
  • 50% Cervical Small Cell Carcinoma 
  • Any stage
  • Demographic, diagnostic data
  • TNM
  • Sample collection date

BOU-9

Ovarian Cancer

Fresh Tissue

Prospective

More than 4 subjects with Primary Ovarian Cancer

  • Freshly resected tissue
  • Any subtype
  • Samples must be received fresh within 24 hours of resection
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Treatment History

BOU-10

Ovarian Cancer

Serum

Retrospective

More than 160 subjects

4 groups:

  • Non-Cancerous Ovarian Disease
  • Early Stage Ovarian Cancer (Stage I)
  • Aggressive Ovarian Cancer (Stage III or IV) with a survival less than 5 years from diagnosis
  • Non-Aggressive Ovarian Cancer (Stage III or IV) with a survival more than 5 years from diagnosis.
  • Samples stored at -80oC
  • No freeze-thaw cycle
  • Demographic, diagnostic data
  • TNM
  • Sample collection date
  • Treatment History

PT-1

Prostate Cancer

FFPE Blocks

Retrospective

More than 150 subjects

5 groups:

  • PrCa patients without recurrence for a minimum of 5 years and who underwent radical prostatectomy and who didn’t receive adjuvant therapy
  • PrCa patients with recurrence (within 3 years) and hormone refractory
  • PrCa patients with recurrence (within 3 years) and hormone sensitive.
  • PrCa patients who underwent transurethral resection of the prostate
  • PrCa patients with metastasis. Hormone refractory
  • Caucasian patients only
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Date of diagnosis
  • PSA at diagnosis
  • PSA after RPE
  • Date of any PSA increase

PT-2

Prostate Cancer

FFPE Blocks

Retrospective

More than 20 subjects Advanced Stage:

  • > or equal to T2 if Gleason score is 8-10
  • > or equal to T3 if Gleason score is > or equal to 7
  • 2 prostate tissue blocks per subject:
    • Primary tumor and matched metastatic sites
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

PT-3

Prostate Cancer

Freshly Resected Tumor Material

Prospective

More than 10 subjects

  • Metastatic castrate-resistant PrCa (CRPC)
  • Sample size: 2 g
  • Samples must be received fresh within 24 hour of resection
  • Age, Ethnicity
  • Sample collection date
  • Tumor Grade and Stage
  • Treatment history

PT-4

Prostate Cancer

Plasma and Tumor Biopsy Samples

Retrospective

More than 120 subjects

3 groups:

  • PrCa patients: positive biopsy
  • Patients: negative biopsy
  • Healthy male controls: only plasma samples
  • Age-matched groups
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Gleason score
  • PSA value

PT-5

Prostate Cancer and Benign Prostate Hyperplasia

Serum

Retrospective

More than 400 subjects

2 groups:

  • Submitted to prostate biopsy and diagnosed with PrCa
  • Submitted to prostate biopsy and diagnosed with Benign Prostate Hyperplasia
  • PSA between 2-10 ng/ml
  • No prior biopsy within 5 years
  • No prior prostate surgery
  • Negative (non-suspicious) Digital Rectal Exam (DRE)
  • Blood samples taken before prostate biopsy
  • Samples stored at -80°C
  • No Hemolytic samples
  • No Samples with multiple freeze thaw cycles
  • Demographic, diagnostic and medical data
  • Sample collection date
  • PSA value
  • Diagnosis at biopsy
  • Positive prostate biopsy: Biopsy Gleason grade

PT-6

Castration-Resistant Prostate Cancer

Whole Blood

Prospective

More than 30 subjects

  • PSA level > 0.2 ng/ml and rising that is documented
  • Blood samples collected in specific RNA Tubes
  • Demographic data
  • Treatment History and medical out-come
  • Treatment history
  • Radiographic progression to confirm CRPC
  • Gleason Score
  • PSA velocity

PT-7

Prostate Cancer

Urine

Prospective

More than 18 subjects

  • Subjects with suspected PrCa (on the basis of abnormal PSA, urinary symptoms, family history of PrCa)
  • Untreated subjects only
  • No Digital Rectal Exam performed within the last 4 hours preceding specimen collection
  • Samples stored at -80°C
  • Age, ethnicity
  • Date of diagnosis
  • Data confirming diagnosis
  • PSA value

BL-1

Urothelial Cell Carcinoma of the Bladder

Fresh Frozen Tissue

Retrospective

More than 150 subjects

6 groups:

  • Ta low grade tumors
  • Ta high grade tumors
  • T1 high grade tumors
  • T2 tumors
  • T3 tumors
  • T4 tumors
  • Minimum of 20 mg of tiissue
  • Demographic, diagnostic and medical data
  • smoking status
  • Clinical history
  • Stage
  • Treatment History and medical out-come

BL-2

Urothelial Cell Carcinoma of the Bladder

Tissue Micro-Arrays

Retrospective

More than 200 subjects

  • Transitional cell carcinomas of the bladder
  • Including Papillary carcinoma, Papillary urothelial neoplasms and Insitu carcinoma
  • Caucasian patients only
  • Diagnosis biopsy or post-treatment biopsy
  • Surgery (partial or radical cystectomy)
  • Primary tumors or metastases
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History (Surgery, Chemotherapy, Biological therapy, Radiation therapy)
  • Medical out-come (2 years)

BL-3

Urothelial Cell Carcinoma of the Bladder

Peripheral Blood Mononuclear Cells

Prospective

More than 25 subjects

  • Advanced stage/higher grade
  • Patients with invasive tumors only
  • Several vials per subject
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • HLA-typing

BL-4

Urothelial Cell Carcinoma of the Bladder

FFPE Blocks

Retrospective

More than 40 subjects:

2 Groups:

  • Invasive cases
  • Non-invasive cases (T1, Ta or Tcis)
  • FFPE blocks must allow the cutting of > 50 sections
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

BL-5

Urothelial Cell Carcinoma of the Bladder

Freshly Resected Tumor Material

Prospective

More than 10 subjects

2 groups:

  • Transitional cell carcinoma
  • Epithelial Bladder Cancer
  • Samples must be received fresh within 24 hour of resection
  • Age, Gender, Ethnicity
  • Tumor Grade and Stage
  • Treatment history (if available)
  • Sample collection date

BL-6

Urothelial Cell Carcinoma of the Bladder

FFPE Blocks

Retrospective

More than 20 subjects

  • Stage III or IV, metastatic or surgically unresectable urothelial carcinoma
  • Primary tumors only
  • Any grade
  • Tissue Samples fixed in 10% Neutral Buffered Formalin (NBF)
  • FFPE blocks should allow the cutting of >50 sections
  • Demographic, diagnostic data
  • Stage (TNM, grade)
  • Sample collection date
  • Histological or cytological evidence of metastatic or surgically unresectalable transitional cell carcinoma

BL-7

Urothelial Cell Carcinoma

FFPE Blocks

Retrospective

More than 160 subjects 3 groups:

  • Non-invasive (stage T1, Ta, Tis)
  • Invasive (stage T2 or higher)
  • Stage III or IV, metastatic/unresectable
  • Diagnosed with Urothelial Cell Carcinoma
  • Age, Gender, Ethnicity
  • Sample collection date
  • Pathological diagnosis
  • Medical history

SK-1

Melanoma

Flash Frozen Tissue

Retrospective

More than 40 Subjects

2 Groups:

  • Patients with more than 12 months survival
  • Patients with less than 12 months survival
  • Patients not treated by immunotherapy
  • Age, gender, ethnicity
  • Clinical history including disease-free survival, 5 years overall survival (if not deceased)
  • Treatment
  • Pathology diagnosis

SK-2

Melanoma

Serum

Retrospective

More than 100 Subjects

3 groups:

  • Group 1 (n=50): Melanoma subjects with a uniform distribution in gender, age, ethnicity, type of melanoma and cancer staging
  • Group 2 (n=30): Patients with benign skin conditions (moles, spitz nevus, seborrheic keratosis) with minimal bias in distribution in gender, age, and ethnicity from group 1 (and no other skin cancer)
  • Group 3 (n=30): Patients without any skin condition, with minimal bias in distribution in gender, age and ethnicity from group 1
  • Samples collected before any treatment or surgery specific to a skin condition
  • Frozen samples
  • Age, gender
  • Sample collection date
  • Date of diagnosis
  • Confirmed diagnosis
  • TNM staging

PED-1

Pediatric Cancer

FFPE Blocks

Retrospective

More than 20 subjects

12 groups:

  • Lymphoma
  • Osteosarcoma
  • Ewing Sarcoma
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Wilms Tumors
  • Medullary thyroid carcinoma
  • Hepatoblastoma
  • Retinoblastoma
  • Hepatoblastoma
  • Pancreatoblastoma
  • Colorectal carcinoma
  • Tissues must have been collected at diagnosis
  • Age, gender
  • Sample collection date
  • Confirmation of pathological diagnosis
  • Date of initial diagnosis
  • Age, gender
  • Sample collection date
  • Confirmation of pathological diagnosis
  • Date of initial diagnosis

PED-2

‘’Healthy” Pediatric Subjects

Fresh Whole Blood

Retrospective

More than 25 subjects

  • Different age groups: 1, 3, 6, 9, and 12 months
  • Whole blood collected by venous sampling in 3 different types of tubes
  • Age
  • Weight
  • Gender

PED-3

Liver Cancer

FFPE Blocks

Retrospective

More than 30 subjects

  • Pediatric Hepatoblastoma
  • Subjects with hepatocellular carcinoma and undifferentiated embryonal sarcoma of the liver
  • Age, gender, ethnicity
  • Sample collection date
  • Tumor stage
  • Treatment history
  • Pathological diagnosis

PED-4

Leigh Syndrome

Plasma

Retrospective

More than 3 subjects

  • Confirmed diagnosis of Leigh syndrome
  • Multiple samples collected overtime from the same patient
  • Age, gender, ethnicity
  • Symptoms and diagnosis report
  • Treatment history

LC-1

Non-Small Cell Lung Carcinoma

FFPE Blocks

Retrospective

More than 3500 subjects

  • 6 FFPE sections for screening of a specific mutation
  • The corresponding FFPE blocks should remain available until the selection of positive blocks is completed
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-2

Non-Small Cell Lung Carcinoma & Squamous Cell Lung Carcinoma

Tissue Microarrays (TMA)

Prospective

More than 1000 subjects

4 groups:

  • 50% Squamous cell Lung Carcinoma
  • 4 groups (one group per stage)
  • 50% Primary Lung Adenocarcinoma
  • 4 groups (one group per stage)
  • SCLC and NSCLC primo diagnosis
  • No Asian subjects
  • Also 5 FFPE slices placed in Eppendorf tube and one stained slide defining the punched area
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade), % tumor cells in sample
  • Smoking status
  • Clinical history including Disease-free survival, Overall survival
  • IHC results

LC-3

Non-Small Cell Lung Cancer (ALK)

FFPE Blocks

Retrospective

More than 150 subjects

  • NSCLC with positive Anaplastic Lymphoma Kinase (ALK+) rearrangements
  • Several biobanks can participate with a minimum of 10 cases/biobank
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Method used for determination of ALK positivity

LC-4

Non-Small Cell Lung Cancer (PD-L1)

Plasma

Prospective

More than 30 subjects

  • Positive for FFPE PD-L1 expression assessed by ICH
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-5

Non-Small Cell Lung Cancer (PD-L1)

FFPE Blocks

Retrospective

More than 30 subjects

  • PD-L1 expression assessed by ICH
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-6

Non-Small Cell Lung Cancer (ALK)

Whole Blood and Matched FFPE Blocks

Prospective

More than 40 subjects

  • 20ml of whole blood
  • The tissue and blood collection must have been done with a maximum of 1 month from each other
  • Whole blood collected in 2 different types of tubes and shipped at room temperature
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

LC-7

Non-Small Cell Lung Cancer (EGFR)

FFPE Blocks

Prospective

More than 40 subjects

  • Locally advanced or metastatic NSCLC – stage IIIB or IV treated by EGFR tyrosine kinase inhibitors
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • EGFR mutation status
  • Treatment History and medical out-come
  • Treatment response to EGFR tyrosine kinase inhibitors treatment

LC-8

Non-Small Cell Lung Cancer (EGFR)

FFPE Blocks

Retrospective

More than 50 subjects

  • Primary tumor or metastasis
  • Progression on prior first-line therapy with different EGFR tyrosine kinase inhibitors
  • Tissue must have been obtained after progression.
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • Mutation data (point mutation in Exons)

LC-9

Non-Small Cell Lung Cancer (EGFR)

Plasma

Prospective

More than 300 subjects

2 groups:

  • Stage III and IV NSCLC with mutated EGFR
  • Stage III and IV NSCLC non-smokers women and/or Asians
  • EDTA plasma aliquoted in 5 Eppendorf tubes
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Alcohol and smoking history

LC-10

Non-Small Cell Lung Carcinoma

FFPE Block and PBMC

Retrospective

More than 50 subjects

  • FFPE block and PBMC collected at diagnosis, before start of any treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • If available, biomarker status: cMET, PI3K, EGFR, PTEN, ALK, ROS1, BRAF, HER2, NRAS…

LC-11

Non-Small Cell Lung Carcinoma

FFPE Blocks

Retrospective

More than 100 subjects

  • FFPE surgery resected tissue blocks
  • Any stage
  • Patients newly diagnosed and prior to treatment
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • 5 years medical follow-up

LC-12

Non-Small Cell Lung Carcinoma

Whole Blood

Retrospective

More than 100 subjects

  • Stage IV NSCLC subjects
  • Only chemotherapy naïve donors
  • Blood sample collected directly into specific tubes and transported at room Temperature (16-25OC)
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

LC-13

Non-Small Cell Lung Cancer

Serum

Retrospective

More than 300 subjects

10 groups

  • Stage I NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
  • Stage I NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
  • Stage I NSCLC adenocarcinoma, never-smokers and survived < 5 years from diagnosis
  • Stage I NSCLC adenocarcinoma, never-smokers who survived > 5 years from diagnosis
  • Stage II NSCLC adenocarcinoma, smokers and survived < 5 years from diagnosis
  • Stage II NSCLC adenocarcinoma, smokers and survived > 5 years from diagnosis
  • Mesothelioma
  • IPF, bronchiectasis, asthma or pulmonary tuberculosis
  • SCLC
  • Healthy control subjects.
  • Collection within 1 month of confirmed diagnosis and prior to start of any drug treatment or surgery
  • Must not have had drug treatment associated to pulmonary disease in the 3 months prior to sample collection 
  • Must not have had surgery associate with pulmonary disease
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Smoking habits

LC-14

Non-Small Cell Lung Cancer (KRAS)

FFPE Blocks

Retrospective

More than 35 subjects

  • Known KRAS codon 12 and 13 mutation status
  • Any NSCLC subtype, any stage
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Method used to detect KRAS mutation

LC-15

Small Cell Lung Carcinoma

FFPE Blocks

Retrospective

More than 180 subjects

  • Any stage
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LC-16

Mesothelioma

FFPE Blocks

Retrospective

More than 180 subjects

  • Samples collected over the past 4 years
  • Age, gender
  • Date of sample collection
  • Stage

OC-1

Uveal Melanoma

FFPE Blocks

Retrospective

More than 15 subjects

  • Diagnosed with Uveal Melanoma
  • Age, Gender, Ethnicity
  • Sample collection date
  • Tumor location and size
  • Pathological diagnosis

OC-2

Parotid Gland Cancer

FFPE Blocks

Retrospective

More than 15 subjects

  • Advanced and metastatic
  • Age, Gender, Ethnicity
  • Medical history
  • Tumor location and size
  • Pathological diagnosis

OC-3

Thyroid Cancer

FFPE and Matched Frozen Tissue

Retrospective

More than 10 subjects

  • 50% Medullary carcinoma and 50% parafollicular hyperplasia
  • Diagnosed with thyroid cancer
  • Age, Gender, Ethnicity
  • Sample collection date
  • Pathological diagnosis
  • Medical history

OC-4

Fallopian Tube Cancer

FFPE Blocks

Retrospective

More than 40 subjects

  • Stage IIIB or higher
  • Age, Gender, Ethnicity
  • TNM
  • Medical history 
  • Pathology diagnosis

OC-5

Pheochromocytoma

Plasma and Matched Frozen Tissue or FFPE

Retrospective

More than 50 subjects

2 groups:

  • 50% subjects with benign pheochromocytoma
  • 50% subjects with malignant pheochromocytoma
  • Pre-surgery plasma samples only
  • Ischemia time < 1 hour for tissue
  • Age, Gender, Ethnicity
  • Sample collection date
  • Clinical data
  • Treatment history

OC-6

Head & Neck Cancer

FFPE

Retrospective

More than 40 subjects

6 groups:

  • Tongue
  • Larynx
  • Nasopharynx
  • Oropharynx
  • Tonsil
  • Hypopharynx
  • Squamous Cell Carcinoma
  • Age, Gender, Ethnicity
  • TNM
  • Clinical data
  • Pathology diagnosis

AD-1

Alzheimer’s Disease

Serum

Retrospective

More than 200 subjects

7 Groups:

  • Mild AD, Moderate AD
  • Mild Cognitive Disorder (MCI) (“AD Converter”)
  • Mild Cognitive Disorder (“Stable MCI”)
  • Lewy Body Dementia
  • Frontotemporal Dementia
  • Vascular Dementia
  • Healthy Controls Retrospective
  • Serum
  • All demographic, and medical data 
  • MMSE and MOCA, scores 
  • CSF Amyloid-ß42, t-Tau, and p-Tau concentrations

AD-2

Alzheimer’s Disease

Plasma

Prospective

More than 100 subjects

4 Groups:

  • Alzheimer’s Disease
  • Frontal Temporal Lobe Dementia
  • Dementia with Lewy Bodies
  • Controls Prospective
  • EDTA plasma 
  • All demographic, and medical data
  • Imaging (PET Scan, MRI) • Cerebrospinal Fluid Tau levels

AD-3

Alzheimer’s Disease

Cerebrospinal Fluid

Retrospective

More than 300 subjects

Different CSF hTau A:

  • 1-42 spanning the entire clinical range Retrospective

 

  • Cerebrospinal fluid samples collected with strictly standardized protocol
  • All demographic, and medical data • MMSE score

AD-4

Alzheimer’s Disease

Frozen Brain Tissue

Retrospective

More than 15 subjects

  • Different pattern for density of alpha-synuclein, tau and amyloid Retrospective
  •  Frozen brain cortical tissue
  • All demographic, and medical data
  • MMSE
  • Braak Stage
  • Neuropathology report

AD-5

Alzheimer’s Disease

Frozen Brain Tissue

Retrospective

More than 40 subjects:

  • Alzheimer’s Disease and age- and gender-matched controls
  • Frozen brain frontal cortical tissue
  • All demographic, and medical data
  • MMSE
  • Braak Stage
  • Neuropathology report

PD-1

Parkinson’s Disease

Cerebrospinal Fluid

Retrospective

More than 30 subjects

3 groups:

  • Parkinson’s Disease without dementia
  • Parkinson’s Disease with dementia
  • Age-matched Control s(“healthy”)
  • Subjects with confirmed Alzheimer’s Disease are excluded
  • Age, Gender, Ethnicity
  • Sample collection date
  • Date of diagnosis
  • Treatment and medical history

PD-2

Parkinson’s Disease

Brain Frozen Tissue

Retrospective

More than 5 subjects

2 groups:

  • Parkinson’s Disease
  • Age-matched control (“healthy”)
  • Brain Temporal Cortical Frozen tissue
  • All samples have histologically confirmed Lewy Body pathology
  • Age, Gender, Ethnicity
  • Clinical and neuropathological diagnosis
  • Clinical History
  • PMI

PD-3

Parkinson’s Disease

Brain FFPE Slides

Retrospective

More than 150 subjects

  • Subjects with leucine-rich repeat kinase 2 (LRRK2) G2019S mutation
  • Brain Tissue Sub-Regions:
    • Dorsolateral Prefrontal Cortex
    • Dorsolateral Amygdala
    • Dorsolateral Putamen
  • Age, Gender, Ethnicity
  • Clinical and neuropathological diagnosis

TBI-1

Traumatic Brain Injury

Plasma

Prospective

More than 250 subjects

  • Glasgow Coma Scale Score between 3 to 15
  • Up to 4 samples collected per subject at different time points after head injury within:
    • 0-3 hours
    • 8-12 hours
    • 24-48 hours
    • 48-72 hours
  • Age, Gender, Ethnicity
  • Date/Time of initial presentation or injury
  • Cause of TBI
  • Other traumatic injuries
  • Date/Time of blood collection
  • GCS score at admission

MS-1

Multiple Sclerosis

Plasma

Retrospective

More than 30 subjects

2 groups:

  • Patients who had an attack within 12 months after treatment initiation
  • Patients without an additional attack and without significant (over 5) new T1/FLAIR lesions in the brain
  • Treated subjects only
  • Age, gender, ethnicity
  • Duration of the disease

MS-2

Multiple Sclerosis

Frozen Brain Tissue

Retrospective

More than 2 subjects

  • Brain tissue regions:
    • Occipital Cortex
    • Cerebellum
    • Pons
    • Temporal Lobe
    • Basal Ganglia
    • Parietal Lobe
    • Frontal Cortex
    • White Matter
    • Cervical Cord
  • Age, gender, ethnicity
  • Duration of the disease
  • PMI

HS-1

Healthy

Whole Blood and Matched Urine

Prospective

More than 120 subjects

3 groups:

  • Aged between 30 and 39 years
  • Aged between 40 and 59 years
  • Aged between 60 and 80 years
  • Donors with any clinical apparent symptoms
  • Donors under any medication are excluded
  • HIV, HCV, HBV seronegative
  • Blood (more than 70ml) collected in different types of tubes at baseline, after 1 month, after 3 months
  • Age, Gender, Ethnicity
  • Laboratory results for complete blood count, coagulation parameters, clinical biochemistry and urinalysis:

HS-2

Healthy

Peripheral Blood Mononuclear Cells

Prospective

More than 10 subjects

  • PBMCs should be frozen in at least 10 aliquots
  • Age, Gender, Ethnicity
  • Sample collection date
  • PBMC count

HS-3

Healthy

Whole Blood

Prospective

At least 6 subjects

  • 50% Male subjects, age-matched
  • 50% Female subjects, age-matched
  • Collected in specific Blood DNA Tubes
  • Samples stored at +4°C right after blood collection
  • Samples must be shipped and received within 3 days after blood draw
  • Age, Gender, Ethnicity • Sample collection date

HS-4

Healthy

Liver FFPE Blocks

Retrospective

At least 12 subjects

  • No malignancy
  • No steatosis
  • No inflammation
  • Age
  • Sample collection date
  • Cause of death
  • PMI

HS-5

Healthy

Cardiac FFPE and Frozen Tissue

Retrospective

At least 3 subjects

  • Tissue from healthy human left cardiac ventricle
  • Short PMI
  • Age, Gender, Ethnicity
  • Sample collection date
  • Cause of death
  • Clinical history
  • PMI

INF-1

Hepatitis B

Serum

Retrospective

More than 400 subjects

4 groups:

  • Genotype A
  • Genotype C
  • Genotype E
  • Genotype F 
  • Patients infected with hepatitis B Virus (HBV), acute or chronic active
  • Samples stored at -20°C
  • Age, gender, ethnicity
  • Country of Origin • Sample collection date
  • Serology

INF-2

HIV and Hepatitis

Frozen EDTA Blood and EDTA Plasma

Prospective

More than 160 subjects

4 groups:

  • HIV-1
  • HIV-2
  • Hepatitis B (HBV)
  • Hepatitis C (HCV)
  • Subjects with confirmed diagnosis with HIV-1 or HIV-2 or HBV or HCV
  • Frozen samples stored at -80°C
  • Age, gender, ethnicity
  • Confirmation of diagnosis
  • Genotype and subtype

INF-3

Human T-Lymphotropic Virus 1 (HTLV-1)

Frozen Serum

Retrospective

More than 80 subjects

  • Healthy or diseased subjects seropositive for Human Y-lymphotropic virus 1 (HTLV-1)
  • Samples stored at -20°C
  • Age, gender
  • Sample collection date
  • Clinical history

INF-4

Human Papilloma Virus (HPV)

Cervical Cytology Samples

Retrospective

More than 120 subjects

4 groups:

  • HPV-positive, low grade
  • HPV-positive, high grade
  • HPV-negative
  • Cervical cancer
  • Diagnosis of HPV infection or of cervical cancer
  • Age, ethnicity
  • Confirmation of diagnosis
  • HPV data and information

INF-5

Brucellosis

Serum

Prospective

10 subjects

  • Subjects with confirmed brucellosis
  • Seropositive for brucellosis
  • Age, gender, ethnicity
  • Confirmation of diagnosis
  • Serological test result
  • Type of test used

INF-6

Parasitic Diseases

Stool

Retrospective

More than 80 subjects

  • Infections due to human parasites
  • Giardia
  • Cryptosporidium
  • Cyclospora, E. histolytical/dispar
  • Hookworm
  • Strongloides
  • Ascaris
  • Dientamoeba fragilis
  • Blastocystis hominis
  • E. nana…
  • Samples must be placed in a specific preservative
  • Results

INF-7

Tuberculosis

Lung FFPE Blocks

Retrospective

At least 10 subjects

  • Acid Fast Bacillus positive
  • Age, gender
  • Sample collection date
  • Pathological diagnosis

RA-1

Rheumatoid Arthritis

Serum

Retrospective

More than 70 subjects

  • Diagnosis of RA more than 1 year
  • Collections at multiple time points including baseline, and multiple serial collections for a minimum of 2yrs
  • Age, gender, ethnicity
  • Disease activity assessment (DAS28)
  • Health assessment questionnaire
  • Radiographic assessment (VdH Score)
  • CRP, CCP, and RF

RA-2

Rheumatoid Arthritis

Serum

Prospective

More than 200 subjects

4 groups:

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Dermatomyositis
  • Several aliquots
  • Age, gender, ethnicity
  • Medical history
  • Treatment history
  • Clinical outcome

PS-1

Psoriasis

Fresh Skin Biopsies

Prospective

More than 20 subjects

  • 3 biopsies per subject from inflamed site
  • Samples shipped immediately after collection at 4°C
  • Age, gender, ethnicity
  • Clinical history
  • Concomitant treatment

PS-2

Psoriasis

Skin FFPE

Retrospective

More than 20 subjects

2 groups:

  • Psoriasis
  • Hidradenitis
  • Skin Fistulae, Sinus or Fissure tissue blocks
  • Fistulising/Sinus-Forming Dermatological Disease
  • Age, gender, ethnicity
  • Concurrent therapies known, including date of last anti-TNF dose

CD-1

Crohn’s Disease

Frozen Intestinal Tissue

Prospective

More than 30 Subjects

  • For each subject: Resections or biopsies of fibrotic tissues and of normal adjacent tissue
  • Age, gender, ethnicity
  • Clinical history
  • Clinical data regarding IBD

CD-2

Crohn’s Disease

Peripheral Blood Mononuclear Cells

Retrospective

More than 24 subjects:

3 groups:

  • Crohn’s Disease
  • Ulcerative Colitis
  • Matched Healthy Controls
  • PBMCs from subjects with active disease and/or in remission
  • Age, gender, ethnicity
  • Date of collection
  • Disease activity at time of collection
  • Treatment history

LE-1

Systemic Lupus Erythematosus

Kidney FFPE Tissue Blocks

Retrospective

More than 30 subjects with Lupus Nephritis

3 groups:

  • No interstitial inflammation
  • Mild interstitial inflammation
  • Moderate/severe interstitial inflammation
  • Kidney biospecimen (biopsies and/or samples from autopsy)
  • Specimen collected within 2 years of initial diagnosis of SLE
  • Age, gender, ethnicity
  • Clinical diagnosis
  • WHO classification for SLE
  • Age of patient at biopsy or sample collection
  • Pathology report

LE-2

Systemic Lupus Erythematosus

Plasma and matched Urine

Prospective

More than 50 subjects

3 groups:

  • SLE
  • Lupus nephritis
  • Matched Healthy controls
  • Subjects diagnosed with SLE with SLE Disease Activity Index (SLEDAI) > 6 and anti-nuclear antibodies (ANA) > 80
  • Subjects diagnosed with LN by biopsy
  • Age, gender, ethnicity
  • Confirmation of diagnosis

SS-1

Primary Sjögren’s Syndrome

Saliva and Tears

Prospective

More than 50

6 subjects

2 groups:

  •  Local and systemic Primary Sjögren’s Syndrome
  • Matched control subjects
  • Whole saliva and parotid saliva
  • Moderate, stable disease
  • Tears collected using Schirmer strips
  • Age, gender, ethnicity
  • Medication
  • Clinical data

TR-1

Heart and Renal Transplant Rejection

RNA and Plasma

Prospective

More than 80 Subjects

4 groups:

  • Acute heart rejection as confirmed by endomyocardial biopsy
  • No heart rejection as confirmed by endomyocardial biopsy
  • Acute kidney rejection as confirmed by kidney biopsy with a Banff grade > 1
  • No kidney rejection as confirmed by kidney biopsy
  • Frozen EDTA Plasma and Isolated RNA
  • Age, gender, ethnicity
  • Treatment history
  • Time duration between post-transplant biopsy and blood sample collection

CLD-1

Celiac Disease

Serum

Retrospective

More than 120 subjects

  • Celiac Disease (non gluten-free diet, biopsy positive)
  • Age, gender, ethnicity
  • Clinical diagnosis of Celiac Disease biopsy report
  • Serological test results

AL-1

Allergy

Serum

Retrospective

More than 25 subjects

  • Tomato Lyc e 2 allergen
  • Age, gender, ethnicity
  • IgE

OD-1

Atopic Dermatitis

Fresh Skin Tissues

Retrospective

More than 10 subjects

  • Skin punch biopsies
  • A diagnosis with moderate to severe AD
  • Samples delivered in tissue culture media within 24 hours at +4°C
  • Age, gender, ethnicity
  • Concurrent disorders
  • Date of sample collection
  • Medical treatment history

OD-2

Diabetes Mellitus

Frozen Liver and Spleen tissues

Retrospective

More than 15 subjects

2 groups:

  •  Diabetes Type I
  • Control, non-diabetic, subjects
  • Subjects between 30 to 65 years
  • Age, gender, ethnicity
  • Weight
  • Medical history

OD-3

Progressive Supranuclear Palsy

Frozen Brain Tissue

Retrospective

More than 2 subjects

  • Caudate Nucleus
  •  Putamen
  • Globus Pallidus
  • Diagnosis of PSP confirmed by immunohistochemistry using anti-tau antibodies
  • Age, gender, ethnicity
  • Medical history
  • Confirmed diagnosis (anti-Tau ICH results)
  • PMI

OD-4

Barrett's Esophagus

Esophagus FFPE Tissue Blocks

Retrospective

More than 15 subjects

  • Esophagus tissue
  • Tissue from resections or biopsies
  • Age, gender, ethnicity
  • Medical history
  • Treatment history

OD-5

Idiopathic Pulmonary Fibrosis

FFPE and Frozen Lung Tissue Blocks and Serum

Prospective

More than 18 subjects

  • Lung tissues samples from resections, biopsies, or autopsy
  • IPF diagnosed with lung biopsy and/or High Resolution Computed Tomography (HCRT)
  • Age, gender, ethnicity
  • Pathology report
  • Clinical Diagnosis method (e.g. HCRT or biopsy/autopsy)
  • Medical history
  • Treatment history

OD-6

Fatty Liver or Non- Alcoholic Steatohepatitis

Liver FFPE slides and Plasma

Retrospective

More than 20 subjects 

2 groups:

  • NASH with mild fibrosis
  • NASH with moderate fibrosis
  • NAFLD fibrosis score
  • Age, gender, ethnicity
  • Duration of the disease
  • Medical history

OD-7

Hypertrophic Cardiomyopathy

Whole Blood

Prospective

More than 200 subjects

  • Diagnosed with Hypertrophic Cardiomyopathy
  • Age, gender, ethnicity
  • Treatment history
  • Disease-causing genetic mutation information

GD-1

Muscular Dystrophy

Frozen Muscular Tissue and Matched Serum

Retrospective

More than 10 subjects

  • Dysferlinopathy and Miyoshi Myopathy
  • Age, gender, ethnicity
  • Sample collection date
  • Date of diagnosis
  • Clinical data

GD-2

Leigh syndrome

Plasma

Retrospective

More than 12 subjects

  • Confirmed diagnosis with Leigh Disease
  • Age, gender, ethnicity
  • Symptoms and diagnosis report
  • Medical history
  • Medical follow-up
  • Treatment history
  • Type of mutations

GD-3

Fabry Disease

Plasma

Retrospective

More than 50 subjects

  • Confirmed diagnosis with Fabry Disease
  • Samples collected prior to Enzyme Replacement Therapy
  • Age, gender, ethnicity
  • Form of disease
  • Medical history
  • Treatment history
  • Type of GLA mutation

GD-4

G6PD deficiency

Whole Blood

Prospective

More than 8 subjects

  • G6PD status determined based on enzymatic activity of G6PD in the subject’s blood samples
  • Age, gender, ethnicity
  • Medical history

LB-1

Colorectal Cancer (KRAS)

Plasma and FFPE Blocks KRAS +

Prospective

More than 200 subjects

  • Newly Diagnosed patients with Colorectal Cancer stage IV
  • Blood samples collected before treatment
  • 20 to 40 40 ml plasma
  • Demographic, diagnostic and medical data
  • Stage
  • KRAS mutation status

LB-2

Non-Small Cell Lung Cancer (ALK)

Whole Blood and FFPE blocks Alk +

Prospective

More than 40 subjects

  • Whole blood collected in different types of tubes and shipped at room temperature
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

LB-3

Non-Small Cell Lung Cancer (EGFR)

Plasma

Prospective

More than 200 subjects

  • Stage III and IV NSCLC with mutated EGFR
  • Stage III and IV NSCLC non-smokers women and/or Asians
  • Plasma aliquoted
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

LB-4

Non-Small Cell Lung Cancer (PD-L1)

Plasma

Prospective

More than 30 subjects

  • Positive for FFPE PD-L1 expression assessed by ICH
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LB-5

Gastric Cancer

PBMC and FFPE Blocks

Retrospective

More than 50 subjects

  • Samples collected at diagnosis, before start of any treatment
  • PBMC isolated from 10 mL of blood
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Biomarker status: EGFR, KRAS,

LB-6

Skin, Lung and Colorectal cancers (BRAFK, EGFR, KRAS)

Urine

Prospective

4 groups:

  • Melanoma BRAF mutated
  • NSCLC EGFR mutated Stage IV
  • NSCLC KRAS mutated Stage IV
  • Colorectal KRAS mutated

 

  • Urine frozen at -80°C
  • Demographic, diagnostic and medical data
  • Stage
  • Treatment History
  • Date of tissue collection
  • Date of urine sampling

BA-1

Troponin I

Plasma

Prospective

More than 200 subjects

8 groups:

  • Below 0.10 ng/ ml
  • 0.10-0.20 ng/ ml
  • 0.20-0.5 ng/ ml
  • 0.5-1.00 ng/ ml
  • 1.00 -2.00 ng/ ml
  • 2.00-5.00 ng/ ml
  • 5.00-10.00 ng/ ml
  • Above 10.0 ng/ ml
  • 5 ml plasma collected according to sponsor protocol
  • Age, gender
  • Sample collection date

BA-2

Thyroid-Stimulating Hormone (TSH)

Plasma and Serum

Prospective

100 subjects

2 groups:

  • Below 0.40 mIU/L
  • Above 10 mIU/L
  • 2ml aliquots
  • Age, gender
  • Sample collection date

BA-3

Procalcitonine

Serum

Retrospective

More than 130 subjects

5 groups:

  • Below 0.5 ng/ ml
  • 0.5-2.00 ng/ ml
  • 2.00 -5.00 ng/ ml
  • 5.00-10.00 ng/ ml
  • Above 10.00 ng/ ml
  • 1ml aliquots
  • Age, gender
  • Sample collection date

BA-4

Vitamin D 25(OH)D

Serum

Prospective

More than 100 subjects

4 groups:

  • Below 20 ng/ ml
  • 20-30 ng/ ml
  • 30-50 ng/ ml
  • Above 50 ng/ ml
  • 5 ml serum
  • Age , gender
  • Sample collection date